VRDN

Viridian is a clinical-stage biopharma whose entire value rests on regulatory approval of its anti-IGF-1R candidates for thyroid eye disease — veligrotug (IV) and elegrobart (SC) — going head-to-head with Amgen's approved Tepezza. The MD&A is explicit that the company is still 'preparing for the anticipated launch of our first commercial product, if approved,' and is only now 'building the infrastructure' for a commercial organization. There is no approved product, and the data provided contains no clinical efficacy results, trial readouts, or approval timeline. That makes this a binary outcome I cannot responsibly underwrite from the figures given — the textbook 'unknowable risk' case.

The income statement confirms the pre-revenue reality. FY2025 'revenue' of $70.8M (up 23,360% off a $302K base) is non-recurring collaboration/licensing income — most likely tied to the Kissei Agreement referenced in the filing — not product sales, so the headline P/S of 27.1x is meaningless. What's real is the cash burn: net loss of -$343M (widening from -$270M), operating loss of -$363M, and operating cash flow of -$276M. Losses are increasing by management's own design ('we expect our losses to increase as our product candidates continue advancing through clinical development').